These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34888210)

  • 1. A Novel Approach for Development of Intraocular Biodegradable Ranibizumab Implant: A Solution for Stability of Protein Activity.
    Dadgar Pakdel F; Mirshahi A; Zahedi P; Mohammad K; Hemmati F; Dadgar Pakdel J; Nicknam MH; Abedin Dorkoosh F
    Adv Pharm Bull; 2021 Sep; 11(4):632-642. PubMed ID: 34888210
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema.
    Zhang Y; Yao Z; Kaila N; Kuebler P; Visich J; Maia M; Tuomi L; Ehrlich JS; Rubio RG; Campochiaro PA
    Ophthalmology; 2014 Nov; 121(11):2237-46. PubMed ID: 25001159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the Ocular Delivery of Ranibizumab.
    Elsaid N; Jackson TL; Elsaid Z; Alqathama A; Somavarapu S
    Mol Pharm; 2016 Sep; 13(9):2923-40. PubMed ID: 27286558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
    Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
    BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
    Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
    Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of stability and biophysical characterization of ranibizumab and aflibercept.
    Moreno MR; Tabitha TS; Nirmal J; Radhakrishnan K; Yee CH; Lim S; Venkatraman S; Agrawal R
    Eur J Pharm Biopharm; 2016 Nov; 108():156-167. PubMed ID: 27615995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term release and stability of pharmaceutical proteins delivered from solid lipid implants.
    Vollrath M; Engert J; Winter G
    Eur J Pharm Biopharm; 2017 Aug; 117():244-255. PubMed ID: 28442372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
    Ozkaya A; Tarakcioglu HN; Tanir I
    Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare resource use and costs of diabetic macular oedema for patients with antivascular endothelial growth factor versus a dexamethasone intravitreal implant in Korea: a population-based study.
    Cho H; Choi KS; Lee JY; Lee D; Choi NK; Lee Y; Bae S
    BMJ Open; 2019 Sep; 9(9):e030930. PubMed ID: 31542758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
    Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D
    Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.
    Hu Q; Li H; Xu W; Du Y; Ma C; He J
    Indian J Ophthalmol; 2019 Nov; 67(11):1800-1809. PubMed ID: 31638037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
    Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P
    Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema.
    Fong AH; Lai TY
    Clin Interv Aging; 2013; 8():467-83. PubMed ID: 23766636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
    Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A
    Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranibizumab and retinal vein occlusion. Too many outstanding questions.
    Prescrire Int; 2012 Sep; 21(130):207. PubMed ID: 23016250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
    Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
    Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population.
    Gu X; Yu X; Song S; Dai H
    Ophthalmic Res; 2017; 58(1):8-14. PubMed ID: 28334720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical appraisal of ranibizumab in the treatment of diabetic macular edema.
    Stewart MW
    Clin Ophthalmol; 2013; 7():1257-67. PubMed ID: 23836955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.